ϳԹ

Hematopoietic Stem and Progenitor Cell Research

The defining properties of multipotent hematopoietic stem cells (HSCs) are their ability to differentiate into multiple lymphoid and myeloid lineages, as well as to self-renew to ensure that the HSC pool is not depleted over the lifespan of an individual. As HSCs proliferate, they progress through a series of lineage commitment steps, producing hematopoietic progenitor cells (HPCs) that are shorter-lived and more restricted in their differentiation potential.

The screening of novel compounds to predict potential toxicity to the hematopoietic system (i.e. hematotoxicity) is an important step in drug development. HemaTox™ assays can assess the toxicity of drugs on the growth and lineage-specific differentiation of human CD34+ hematopoietic stem and progenitor cells (HSPCs) into one of three specific progenitor cell lineages (erythroid, myeloid, or megakaryocyte).

Explore our scientific resources below to learn more about how to source, culture, and analyze HSPCs.

Set Descending Direction
View as Grid List Text Only

Products 61 to 72 of 76 total

  1. New Tools for the Ex Vivo Expansion of Human Hematopoietic Stem and Progenitor Cells
    New Tools for the Ex Vivo Expansion of Human Hematopoietic Stem and Progenitor Cells
    The development of standardized ex vivo HSPC expansion methods is needed to generate clinically relevant cell numbers for transplantation. This webinar will review key concepts in human HSPC biology, including standardized methods and recently demonstrated strategies for expanding HSPCs in culture. Additionally, ϳԹ products for the entire workflow of HSPC expansion will be covered, from isolation to expansion and differentiation, and analysis.
Set Descending Direction
View as Grid List Text Only

Products 61 to 72 of 76 total